Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Novartis. News release: Novartis’ cosentyx superior to stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks. 2016 Mar 5.
2. Eli Lilly and Co. News release: Studies show ixekizumab improved work productivity for patients with moderate to severe plaque psoriasis: Results published in JAMA Dermatology. 2016 Mar 7.